Spots Global Cancer Trial Database for recurrent lymphoplasmacytic lymphoma

Every month we try and update this database with for recurrent lymphoplasmacytic lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01955499	Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Lenalidomide Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	NCT01076543	AIDS-Related Ho... Recurrent Adult... Recurrent Folli... Recurrent Lymph... Recurrent Margi... Recurrent Non-H... Recurrent T-Cel... Waldenstrom Mac...	Laboratory Biom... Lenalidomide Temsirolimus	18 Years -	National Cancer Institute (NCI)
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02950220	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Mediastinal Lym... Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	NCT04578600	Indolent B-Cell... Recurrent B-Cel... Recurrent Chron... Recurrent Mucos... Recurrent Folli... Recurrent Hairy... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Chro... Refractory Muco... Refractory Foll... Refractory Hair... Refractory Lymp... Refractory Mant... Refractory Marg... Recurrent Small... Refractory Smal...	Lenalidomide Obinutuzumab Oral Azacitidin...	18 Years -	University of California, Davis

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: